Current developments in neurology, Part I: Advances in the pharmacotherapy of headache, epilepsy, and multiple sclerosis.
When caring for patients with disorders of the central nervous system such as migraine headaches, epilepsy, or MS, clinicians are faced with increasingly complex pharmacotherapeutic options. Pharmacotherapeutic strategies directed toward prevention, reversal, or cure of these diseases are hampered by an incomplete understanding of the underlying pathophysiology. In this decade of the brain, basic science research combined with difficult but necessary clinical trials may answer some seemingly overwhelming questions for these devastating illnesses.
Gidal
B E
BE
School of Pharmacy, University of Wisconsin, Madison 53706, USA.
Wagner
M L
ML
Privitera
M D
MD
Dalmady-Israel
C
C
Crismon
M L
ML
Fagan
S C
SC
Graves
N M
NM
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000281:Administration, Intranasal; D000284:Administration, Oral; D000927:Anticonvulsants / Q000627:therapeutic use; D004087:Dihydroergotamine / Q000627:therapeutic use; D004828:Epilepsies, Partial / Q000188:drug therapy*; D018755:GABA Agonists / Q000494:pharmacology; D006801:Humans; D007278:Injections, Spinal; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000927:Anticonvulsants; D018755:GABA Agonists; D014662:Vasoconstrictor Agents; D000068576:Interferon beta-1b; D004087:Dihydroergotamine; D016899:Interferon-beta; D000068556:Interferon beta-1a